Endo v. Nexus Pharmaceuticals: Emerphed RTU Syringe Patent Action Settles
Endo USA and Endo Operations Limited brought a three-patent infringement action against Nexus Pharmaceuticals over its Emerphed RTU pre-filled syringes in the Northern District of Illinois. The parties reached a confidential Settlement and License Agreement, resolving all claims without prejudice in 312 days — suggesting a negotiated commercial resolution rather than a merits adjudication.
Three-patent RTU syringe dispute ends in confidential licence
On 6 June 2024, Endo USA, Inc. and Endo Operations Limited filed a patent infringement action against Nexus Pharmaceuticals, LLC in the Northern District of Illinois before Judge April M. Perry. The complaint centred on Nexus’s Emerphed RTU (ready-to-use) pre-filled syringes, asserting infringement of three U.S. patents — US11491121B2, US10869845B1, and US12029710B2 — each directed to formulations and methods relating to injectable ephedrine products.
On 11 April 2025, after 312 days of litigation, the parties filed a joint stipulation dismissing all claims, counterclaims, and affirmative defenses without prejudice. The dismissal followed execution of a confidential Settlement and License Agreement, the terms of which are not part of the public record. Each party agreed to bear its own legal costs, and the court retained jurisdiction to enforce the settlement — a standard mechanism that preserves judicial oversight of compliance.
The 312-day resolution is notably swift for a multi-patent pharmaceutical case, which typically proceeds to claim construction and beyond before any resolution. The existence of a license agreement — rather than a pure dismissal — suggests Nexus secured some continued commercial pathway for Emerphed RTU, though the scope and royalty structure remain unknown. Whether Endo viewed the license as commercially protective or made concessions to avoid costly litigation uncertainty is not discernible from the public record.
Filing to Voluntary dismissal in 312 days
312 days — resolved faster than the median U.S. pharma patent trial, which typically exceeds 2 years
Voluntarily dismissed: what the settlement structure means for both parties
Dismissal without prejudice following a licensing deal
A voluntary dismissal without prejudice means neither party obtained a merits ruling — the case ended by mutual agreement, not judicial decision. Crucially, the stipulation references a confidential Settlement and License Agreement as the commercial vehicle resolving the dispute. The court retaining jurisdiction to enforce this agreement is significant: it allows either party to return to court if the other breaches the settlement without needing to refile the original action.
No merits adjudicationWithout prejudice: public record is silent on full terms
The stipulation specifies dismissal ‘without prejudice,’ meaning Endo retains the theoretical right to refile patent infringement claims if future circumstances — such as a breach of the license — warrant it. This is distinct from a dismissal with prejudice, which would bar refiling permanently. However, the practical effect of the Settlement and License Agreement may functionally resolve the underlying dispute. Because the agreement is confidential, the precise scope of any licence grant or limitations on Nexus’s commercial activities cannot be confirmed from public filings.
Without prejudice confirmedNexus likely secures a licence to continue Emerphed RTU sales
The structure of the resolution — a Settlement and License Agreement rather than an injunction or consent judgment — is consistent with Nexus obtaining a licence to practise one or more of the asserted patents. This would allow Nexus to continue commercialising Emerphed RTU syringes, subject to undisclosed terms. Nexus avoided a potentially adverse merits ruling across three patents, which typically represents a material litigation risk reduction, particularly given Endo’s portfolio breadth in this product category.
Likely licensed, not enjoinedEndo monetises its RTU syringe portfolio through negotiated licence
For Endo, a confidential licence rather than a court victory represents a commercially pragmatic outcome. The patents remain unchallenged on the merits — preserving their enforceability and deterrent value against other potential infringers in the ready-to-use ephedrine market. Each party bearing its own costs suggests a balanced negotiation rather than a clear leverage imbalance. Endo’s retained portfolio of three patents covering this product space remains a tool for future enforcement or licensing discussions with other market participants.
Portfolio enforceability preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Endo USA, Inc | Company | Pharmaceutical company — holder of US11491121B2, US10869845B1, and US12029710B2Search in Eureka ↗ |
| Co-Plaintiff | ENDO OPERATIONS LIMITED | Individual | Search in Eureka ↗ |
| Defendant | Nexus Pharmaceuticals, LLC | Company | Specialty pharmaceutical company commercialising Emerphed RTU pre-filled ephedrine syringesSearch in Eureka ↗ |
| Plaintiff counsel | Aziz Burgy | Attorney | Counsel for Endo USA, IncSearch in Eureka ↗ |
| Plaintiff counsel | James Lee Lovsin | Attorney | Counsel for Endo USA, IncSearch in Eureka ↗ |
| Plaintiff counsel | Rebecca Clegg | Attorney | Counsel for Endo USA, IncSearch in Eureka ↗ |
| Plaintiff counsel | Ricardo Camposanto | Attorney | Counsel for Endo USA, IncSearch in Eureka ↗ |
| Plaintiff law firm | Axinn Veltrop & Harkrider | Law Firm | Representing Endo USA, IncSearch in Eureka ↗ |
| Plaintiff law firm | McDonnell, Boehnen, Hulbert & Berghoff LLP | Law Firm | Representing Endo USA, IncSearch in Eureka ↗ |
| Defendant counsel | Isha S. Shah | Attorney | Counsel for Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | John Randolph Labbe | Attorney | Counsel for Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Julianne Marie Hartzell | Attorney | Counsel for Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Michael R. Weiner | Attorney | Counsel for Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Thomas Robert Burns | Attorney | Counsel for Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant law firm | Marshall Gerstein & Borun LLP | Law Firm | Representing Nexus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Presiding judge | Judge April M. Perry | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language — ‘all claims, counterclaims and affirmative defenses are hereby dismissed without prejudice’ — reflects a negotiated exit rather than a judicial finding on infringement, validity, or enforceability. The explicit reference to a confidential Settlement and License Agreement as the basis for resolution confirms this was a commercial deal, not a litigation concession. The retention of court jurisdiction to enforce the agreement elevates the settlement beyond a simple voluntary dismissal, creating a court-supervised compliance mechanism that carries contempt exposure for breach.
US11491121B2, US10869845B1 & US12029710B2 — Ready-to-use ephedrine syringe formulations
The three patents at issue — US11491121B2, US10869845B1, and US12029710B2 — cover formulations, compositions, and associated methods relating to ready-to-use (RTU) injectable ephedrine products, the technology underlying Endo’s branded Vasostrict and related vasopressor syringe lines. RTU formulations are clinically significant because they eliminate the need for dilution prior to administration, reducing preparation errors in acute care settings. The application dates span multiple filing years, reflecting a layered patent strategy designed to extend portfolio protection across successive product generations.
In the competitive landscape for hospital-use vasopressor injectables, RTU pre-filled syringes have become a high-value category. Endo’s three-patent portfolio creates overlapping protection — making it difficult for a competitor to design around a single patent without potentially infringing another. For pharmaceutical manufacturers developing ephedrine or related vasopressor RTU syringes, these patents collectively represent a significant freedom-to-operate risk. The confidential licence granted to Nexus does not affect the patents’ enforceability against third parties, and all three remain valid and in force.
Should you run an FTO analysis against US11491121B2, US10869845B1, and US12029710B2?
Any company developing, manufacturing, or commercialising ready-to-use pre-filled injectable syringes — particularly those containing ephedrine or related vasopressors — should treat Endo’s three-patent portfolio as a primary FTO concern. The fact that Nexus required a licence to proceed with Emerphed RTU confirms that commercial launch without a clearance opinion carries material infringement exposure. ANDA filers, contract manufacturers, and hospital formulary suppliers operating in this space are all potentially within scope.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory affairs teams to map their specific formulation parameters against the claim sets of US11491121B2, US10869845B1, and US12029710B2 simultaneously. By identifying overlapping claim elements across all three patents, Eureka helps product teams pinpoint design-around opportunities or flag licensing necessity before clinical or commercial investment escalates — reducing the risk of a multi-patent assertion like the one Nexus faced.
Run a freedom-to-operate analysis on US11491121B2 to assess your product’s exposure
Run FTO in Eureka →Similar RTU syringe and injectable pharmaceutical patent cases
Cases involving ready-to-use injectable formulation patents in the Northern District of Illinois and comparable federal venues, including vasopressor and ephedrine syringe disputes.
What this case signals for the injectable pharmaceutical IP landscape
Three asserted patents, a confidential licence, and a 312-day close — this case illustrates how RTU syringe IP disputes are increasingly resolved commercially.
RTU syringe formulations are an active patent enforcement target
Endo’s willingness to assert three patents simultaneously against a single RTU syringe product signals aggressive portfolio enforcement in the pre-filled injectable space. Companies developing or commercialising ready-to-use ephedrine or related vasopressor syringes should expect similar multi-patent exposure and should conduct thorough FTO analysis before market entry.
Early settlement with licensing is the dominant resolution pattern in pharma patent disputes
Resolving in under a year — before claim construction — suggests both parties valued commercial certainty over litigation outcomes. This pattern is common in specialty pharma: patent holders extract licensing revenue; challengers preserve commercial access. Monitoring settlement timelines in comparable RTU syringe cases can help calibrate negotiation strategy and litigation budget expectations.
Endo v Nexus — key questions answered
Endo asserted three U.S. patents: US11491121B2, US10869845B1, and US12029710B2. All three relate to ready-to-use injectable ephedrine formulations and were asserted in connection with Nexus’s Emerphed RTU pre-filled syringes in the Northern District of Illinois.
The case was resolved through a confidential Settlement and License Agreement. All claims, counterclaims, and affirmative defenses were dismissed without prejudice. Each party bore its own costs and attorneys’ fees. The court retained jurisdiction to enforce the settlement, which was filed on 11 April 2025 after approximately 312 days of litigation.
A dismissal without prejudice technically preserves Endo’s right to refile infringement claims against Nexus. However, the Settlement and License Agreement in place likely governs Nexus’s authorised use of the patents. In practice, a breach of the licence terms — rather than a fresh infringement — would more likely trigger enforcement, using the court’s retained jurisdiction rather than a new filing.
The dispute centred on Nexus’s Emerphed RTU Syringes — a ready-to-use pre-filled injectable ephedrine product used in acute care and surgical settings. Endo alleged that the design and formulation of this product infringed its portfolio of three U.S. patents directed to RTU ephedrine injectable formulations.
Endo was represented by Axinn Veltrop & Harkrider and McDonnell, Boehnen, Hulbert & Berghoff LLP, with attorneys including Aziz Burgy, James Lee Lovsin, Rebecca Clegg, and Ricardo Camposanto. Nexus was represented by Marshall Gerstein & Borun LLP, with attorneys including Isha S. Shah, John Randolph Labbe, Julianne Marie Hartzell, Michael R. Weiner, and Thomas Robert Burns.
PatSnap Eureka searches patents and litigation data to answer instantly.